Replies to post #77382 on Biotech Values

[DewDiligence]

Re: Which generic-drug companies will benefit?

With so many blockbuster drugs coming off patent between 2010-2014 as the article states, who are some of "the best" generic drug makers likely to prosper?

For small-molecule drugs, TEVA, MYL, and WPI figure to be the main beneficiaries of blockbusters going off-patent in the US and other developed markets. For biologics and complex-mixture drugs, it’s a whole different ballgame—the beneficiaries of blockbusters going off-patent are likely to include TEVA, Sandoz (with help from MNTA), and some of the traditional Big Pharma companies such as MRK.